注射用吉西他滨联合顺铂在非小细胞肺癌患者治疗中的应用效果分析  

Analysis of the Application Effect of Gemcitabine for Injection Combined with Cisplatin in the Treatment of Patients With Non-small Cell Lung Cancer

作　　者：张楷杰 崔敏 程杰 李仙仙 ZHANG Kaijie;CUI Min;CHENG Jie;LI Xianxian(Hematology and Oncology Department,Heji Hospital Affiliated to Changzhi Medical College,Changzhi,Shanxi,046000,China;Clinical Skills Center,Changzhi Medical College,Changzhi,Shanxi,046000,China)

机构地区：[1]长治医学院附属和济医院血液肿瘤内科,山西长治046000 [2]长治医学院临床技能中心,山西长治046000

出　　处：《中外医疗》2024年第28期1-4,共4页China & Foreign Medical Treatment

基　　金：长治医学院附属和济医院2020年科研孵育项目(202212)。

摘　　要：目的分析注射用吉西他滨结合顺铂在非小细胞肺癌患者治疗中的疗效。方法方便选取2022年1月—2023年12月长治医学院附属和济医院收治的86例非小细胞肺癌患者为研究对象,根据不同的治疗方法将其分为对照组(43例,行常规治疗)、观察组(43例,采取注射用吉西他滨联合顺铂治疗),比较两组的治疗效果、不良反应发生率、免疫功能、肿瘤标志物水平。结果观察组的治疗有效率为86.05%(37/43),高于对照组的60.47%(26/43),差异有统计学意义(χ^(2)=7.181,P<0.05)。治疗后,观察组免疫功能高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,观察组肿瘤标志物水平低于对照组,差异有统计学意义(P<0.05)。结论在非小细胞肺癌患者治疗中联合使用顺铂和吉西他滨,能够降低肿瘤标志物水平,改善免疫功能,减少不良反应,提升临床疗效。Objective To analyze the efficacy of gemcitabine for injection combined with cisplatin in the treatment of patients with non-small cell lung cancer.Methods 86 patients with non-small cell lung cancer admitted to Heji Hospital Affiliated to Changzhi Medical College from January 2022 to December 2023 were conveniently selected as the research objects.According to different treatment methods,they were divided into control group(43 cases,routine treatment)and observation group(43 cases,gemcitabine for injection combined with cisplatin treatment).The therapeutic effect,the incidence of adverse reactions,immune function and the level of tumor markers in the two groups were compared.Results The effective rate of treatment in the observation group was 86.05%(37/43),which was higher than 60.47%(26/43)in the control group,and the difference was statistically significant(χ^(2)=7.181,P<0.05).After treatment,the immune function of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the level of tumor markers in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of cisplatin and gemcitabine in the treatment of patients with non-small cell lung cancer can reduce the level of tumor markers,improve immune function,reduce adverse reactions,and improve clinical efficacy.

关 键 词：非小细胞肺癌 顺铂 吉西他滨 治疗效果 不良反应 

分 类 号：R563[医药卫生—呼吸系统]